Dexamethasone inhibits mucosal adaptation after small bowel resection

Area of Science:

• Gastroenterology
• Endocrinology
• Cell Biology

Background:

• Massive small bowel resection triggers mucosal adaptation.
• Dexamethasone is a potent glucocorticoid with known effects on growth and metabolism.

Purpose of the Study:

• To investigate the impact of dexamethasone on mucosal adaptation following significant small bowel resection in rats.
• To explore the role of insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs) in mediating dexamethasone's effects.

Main Methods:

• Rats underwent 80% jejunoileal resection or sham operation.
• Dexamethasone or vehicle was administered subcutaneously for 7 days.
• Mucosal weight, DNA, protein content, and disaccharidase activities were measured.
• Serum levels of IGF-I, IGF-II, and various IGFBPs were quantified.

Main Results:

• Dexamethasone decreased mucosal weight, DNA, and protein content in both sham and resected rats.
• Dexamethasone increased duodenojejunal enzyme activities but had varied effects in the ileum, particularly blunted in resected rats.
• Serum IGF-I and IGF-II levels decreased, while IGFBP-1 increased and IGFBP-2 decreased with dexamethasone treatment.
• IGFBP-3 levels were reduced by dexamethasone and resection.

Conclusions:

• Dexamethasone inhibits small intestinal mucosal adaptation and growth, an effect potentially mediated by reduced IGF levels.
• Alterations in IGF binding protein profiles may also contribute to the observed growth-inhibiting effects of dexamethasone.
• These findings highlight the complex interplay between glucocorticoids, growth factors, and intestinal adaptation.